- Home
- CATO vs RGLS Comparison
CATO vs RGLS Comparison
Compare CATO & RGLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CATO
- RGLS
- Stock Information
- Founded
- CATO 1946
- RGLS 2007
- Country
- CATO United States
- RGLS United States
- Employees
- CATO N/A
- RGLS N/A
- Industry
- CATO Clothing/Shoe/Accessory Stores
- RGLS Biotechnology: Pharmaceutical Preparations
- Sector
- CATO Consumer Discretionary
- RGLS Health Care
- Exchange
- CATO Nasdaq
- RGLS Nasdaq
- Market Cap
- CATO 77.6M
- RGLS 102.1M
- IPO Year
- CATO N/A
- RGLS 2012
- Fundamental
- Price
- CATO $3.46
- RGLS $1.23
- Analyst Decision
- CATO
- RGLS Strong Buy
- Analyst Count
- CATO 0
- RGLS 6
- Target Price
- CATO N/A
- RGLS $10.33
- AVG Volume (30 Days)
- CATO 194.9K
- RGLS 281.3K
- Earning Date
- CATO 11-21-2024
- RGLS 11-07-2024
- Dividend Yield
- CATO 19.71%
- RGLS N/A
- EPS Growth
- CATO N/A
- RGLS N/A
- EPS
- CATO N/A
- RGLS N/A
- Revenue
- CATO $666,779,000.00
- RGLS N/A
- Revenue This Year
- CATO N/A
- RGLS N/A
- Revenue Next Year
- CATO N/A
- RGLS N/A
- P/E Ratio
- CATO N/A
- RGLS N/A
- Revenue Growth
- CATO N/A
- RGLS N/A
- 52 Week Low
- CATO $3.02
- RGLS $1.08
- 52 Week High
- CATO $7.37
- RGLS $3.79
- Technical
- Relative Strength Index (RSI)
- CATO 38.46
- RGLS 30.55
- Support Level
- CATO $3.66
- RGLS $1.49
- Resistance Level
- CATO $4.10
- RGLS $1.64
- Average True Range (ATR)
- CATO 0.29
- RGLS 0.11
- MACD
- CATO 0.01
- RGLS -0.04
- Stochastic Oscillator
- CATO 10.99
- RGLS 11.68
About CATO Cato Corporation (The)
The Cato Corp operates as a specialty retailer of fashion apparel and accessories primarily in the southeastern United States. Its primary objective is to be the fashion specialty retailer for fashion and value in its markets. The company operates through the following business segments: Retail and Credit. The Retail segment which generates the majority of revenue offers fashion specialty stores. The Credit segment involves credit card services.
About RGLS Regulus Therapeutics Inc.
Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.